Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
Marx N, Deanfield J, Mann J, Arechavaleta R, Bain S, Bajaj H, Tanggaard K, Birkenfeld A, Buse J, Davicevic-Elez Z, Desouza C, Emerson S, Engelmann M, Hovingh G, Inzucchi S, Jhund P, Mulvagh S, Pop-Busui R, Poulter N, Rasmussen S, Tu S, McGuire D, Group O. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation 2025, 151: 1639-1650. PMID: 40156843, PMCID: PMC12144549, DOI: 10.1161/circulationaha.125.074545.Peer-Reviewed Original ResearchConceptsOral semaglutideType 2 diabetesAdverse cardiovascular eventsCardiovascular eventsCardiovascular outcomesAdverse cardiovascular events outcomeEffects of oral semaglutidePrimary outcomeMajor adverse cardiovascular events outcomeAdverse event profilePrimary outcome eventNonfatal myocardial infarctionChronic kidney diseaseAtherosclerotic cardiovascular diseaseCardiovascular event outcomesSGLT2i treatmentSGLT2i useReceptor agonistsAdverse eventsPrespecified analysesFollow-upCardiovascular deathRandomized trialsSemaglutideNonfatal stroke
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply